R&D from the Comfort of an Attic

May 17, 2011

Despite having seven employees who all work from home, FerroKin Biosciences plans to bring a drug to market in 2015, reports The Atlantic's Quinn Norton. This low overhead model, Norton adds, allows the companies to focus on nice drugs, and the one FerroKin is developing is to treat congenital anemias.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

More Details Wanted

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

And a Third

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

Glimpses of Viral Origins

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

PLOS Papers on Plasmodium Falciparum Populations, Scabies Molecular Diagnostics, More

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.

Menu